Real-world clinical experience with secukinumab in psoriatic arthritis: an observational study and a literature review
Objective. Psoriatic arthritis (PsA) can be treated with biological drugs targeting IL-17A, such as secukinumab, with good responses and long-term positive outcomes in clinical studies. Methods. An observational study was conducted on adult subjects with PsA and comorbidities, treated with secuki...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2025-01-01
|
| Series: | Reumatismo |
| Subjects: | |
| Online Access: | https://www.reumatismo.org/reuma/article/view/1694 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832583899546386432 |
|---|---|
| author | Eleonora Celletti Giulio Gualdi Emanuela Sabatini Francesco Cipollone Fabio Lobefaro Paolo Amerio |
| author_facet | Eleonora Celletti Giulio Gualdi Emanuela Sabatini Francesco Cipollone Fabio Lobefaro Paolo Amerio |
| author_sort | Eleonora Celletti |
| collection | DOAJ |
| description |
Objective. Psoriatic arthritis (PsA) can be treated with biological drugs targeting IL-17A, such as secukinumab, with good responses and long-term positive outcomes in clinical studies.
Methods. An observational study was conducted on adult subjects with PsA and comorbidities, treated with secukinumab after prior therapy with conventional disease-modifying anti-rheumatic drugs or biological agents that were discontinued due to lack of efficacy or adverse drug reactions. Patients were followed up with clinical visits at 3, 6, 9, and 12 months and evaluated for disease activity, pain, and quality of life, with respect to values recorded at baseline. Moreover, a narrative review of the literature was performed on secukinumab’s use for PsA in real life.
Results. Fifteen patients completed 6 months of follow-up, eleven patients completed 9 months, and six patients were followed for 12 months. The major comorbidities recorded were fibromyalgia (33% of patients), recurrent bilateral anterior uveitis, and autoimmune thyroiditis with hypothyroidism (both 13% of the patients). A significant improvement in Disease Activity Score-28 was recorded at 6 and 9 months, while a significant difference vs. baseline was seen at 3, 6, and 9 months for the Psoriasis Area Severity Index. The Bath Ankylosing Spondylitis Disease Activity Index showed significant differences vs. baseline at 9 and 12 months. There was an improving trend at 9 and 12 months for pain scores and a significant improvement at 6 and 9 months for the physical component and at 12 months for the social component (Short Form 36 Health Survey quality of life scores). For the review of the literature, 35 articles were identified but only 17 papers were eventually considered.
Conclusions. Secukinumab has demonstrated effectiveness for PsA treatment in several real-world studies. Both patient-oriented and clinician-oriented outcomes showed a significant improvement with this treatment. The present real-world evaluation adds further evidence of the use of secukinumab for PsA treatment, showing the rapid, safe, clinically significant, and sustained responses of PsA patients affected by co-morbidities.
|
| format | Article |
| id | doaj-art-d7af1e887238447da319f31e3ccea0e2 |
| institution | Kabale University |
| issn | 0048-7449 2240-2683 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Reumatismo |
| spelling | doaj-art-d7af1e887238447da319f31e3ccea0e22025-01-28T02:31:55ZengPAGEPress PublicationsReumatismo0048-74492240-26832025-01-0110.4081/reumatismo.2025.1694Real-world clinical experience with secukinumab in psoriatic arthritis: an observational study and a literature reviewEleonora Celletti0Giulio Gualdi1https://orcid.org/0000-0002-1640-6609Emanuela Sabatini2Francesco Cipollone3Fabio Lobefaro4Paolo Amerio5Rheumatology Service, Medical Clinic, ASL 2 Abruzzo, G. d’Annunzio University, ChietiUnit of Dermatology, Department of Medicine and Aging Science, G. d’Annunzio University, ChietiRheumatology Service, Medical Clinic, ASL 2 Abruzzo, G. d’Annunzio University, ChietiRheumatology Service, Medical Clinic, ASL 2 Abruzzo, G. d’Annunzio University, ChietiUnit of Dermatology, Department of Medicine and Aging Science, G. d’Annunzio University, ChietiUnit of Dermatology, Department of Medicine and Aging Science, G. d’Annunzio University, Chieti Objective. Psoriatic arthritis (PsA) can be treated with biological drugs targeting IL-17A, such as secukinumab, with good responses and long-term positive outcomes in clinical studies. Methods. An observational study was conducted on adult subjects with PsA and comorbidities, treated with secukinumab after prior therapy with conventional disease-modifying anti-rheumatic drugs or biological agents that were discontinued due to lack of efficacy or adverse drug reactions. Patients were followed up with clinical visits at 3, 6, 9, and 12 months and evaluated for disease activity, pain, and quality of life, with respect to values recorded at baseline. Moreover, a narrative review of the literature was performed on secukinumab’s use for PsA in real life. Results. Fifteen patients completed 6 months of follow-up, eleven patients completed 9 months, and six patients were followed for 12 months. The major comorbidities recorded were fibromyalgia (33% of patients), recurrent bilateral anterior uveitis, and autoimmune thyroiditis with hypothyroidism (both 13% of the patients). A significant improvement in Disease Activity Score-28 was recorded at 6 and 9 months, while a significant difference vs. baseline was seen at 3, 6, and 9 months for the Psoriasis Area Severity Index. The Bath Ankylosing Spondylitis Disease Activity Index showed significant differences vs. baseline at 9 and 12 months. There was an improving trend at 9 and 12 months for pain scores and a significant improvement at 6 and 9 months for the physical component and at 12 months for the social component (Short Form 36 Health Survey quality of life scores). For the review of the literature, 35 articles were identified but only 17 papers were eventually considered. Conclusions. Secukinumab has demonstrated effectiveness for PsA treatment in several real-world studies. Both patient-oriented and clinician-oriented outcomes showed a significant improvement with this treatment. The present real-world evaluation adds further evidence of the use of secukinumab for PsA treatment, showing the rapid, safe, clinically significant, and sustained responses of PsA patients affected by co-morbidities. https://www.reumatismo.org/reuma/article/view/1694Psoriatic arthritissecukinumabreal-world evidencecomorbidity |
| spellingShingle | Eleonora Celletti Giulio Gualdi Emanuela Sabatini Francesco Cipollone Fabio Lobefaro Paolo Amerio Real-world clinical experience with secukinumab in psoriatic arthritis: an observational study and a literature review Reumatismo Psoriatic arthritis secukinumab real-world evidence comorbidity |
| title | Real-world clinical experience with secukinumab in psoriatic arthritis: an observational study and a literature review |
| title_full | Real-world clinical experience with secukinumab in psoriatic arthritis: an observational study and a literature review |
| title_fullStr | Real-world clinical experience with secukinumab in psoriatic arthritis: an observational study and a literature review |
| title_full_unstemmed | Real-world clinical experience with secukinumab in psoriatic arthritis: an observational study and a literature review |
| title_short | Real-world clinical experience with secukinumab in psoriatic arthritis: an observational study and a literature review |
| title_sort | real world clinical experience with secukinumab in psoriatic arthritis an observational study and a literature review |
| topic | Psoriatic arthritis secukinumab real-world evidence comorbidity |
| url | https://www.reumatismo.org/reuma/article/view/1694 |
| work_keys_str_mv | AT eleonoracelletti realworldclinicalexperiencewithsecukinumabinpsoriaticarthritisanobservationalstudyandaliteraturereview AT giuliogualdi realworldclinicalexperiencewithsecukinumabinpsoriaticarthritisanobservationalstudyandaliteraturereview AT emanuelasabatini realworldclinicalexperiencewithsecukinumabinpsoriaticarthritisanobservationalstudyandaliteraturereview AT francescocipollone realworldclinicalexperiencewithsecukinumabinpsoriaticarthritisanobservationalstudyandaliteraturereview AT fabiolobefaro realworldclinicalexperiencewithsecukinumabinpsoriaticarthritisanobservationalstudyandaliteraturereview AT paoloamerio realworldclinicalexperiencewithsecukinumabinpsoriaticarthritisanobservationalstudyandaliteraturereview |